Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04734106 · ClinicalTrials.gov registry record · Early Phase 1
Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis
A Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04734106: Recruiting Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome, sponsored by Wake Forest University Health Sciences.
NCT04734106 is a Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 30 participants, below the 361-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04734106, a Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and efficacy of super-concentrated, freeze-dried aloe vera capsules for treatment of interstitial cystitis.
Primary Outcome
Non-serious adverse events will be defined as any new medical condition or worsening of an existing medical condition, not to include the disease being studied. Severe adverse events will be defined as any adverse event that results in death, a life-threatening event, inpatient hospitalization, prolongation of existing hospitalization (hospitalization for an elective treatment of a pre-existing condition will not be considered a serious event), disability or incapacity, or an important medical e
Conditions Studied
Interventions
- DRUG Desert Harvest Aloe Vera Capsules
- OTHER Placebo Capsules
Study Locations (1)
North Carolina
- Wake Forest Baptist Hospital - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2027-07 |
| Phase | Early Phase 1 |
What NCT04734106 shows while recruiting
NCT04734106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 361-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Interstitial Cystitis appearing as the primary indexed condition, and to 2 interventions - of which Desert Harvest Aloe Vera Capsules is the first listed.
NCT04734106 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04734106 about?
NCT04734106 is a clinical study titled "Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis". The purpose of this study is to assess the safety and efficacy of super-concentrated, freeze-dried aloe vera capsules for treatment of interstitial cystitis.
What is the current status of trial NCT04734106?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-02-18. Estimated completion is 2027-07.
What conditions does trial NCT04734106 study?
This clinical trial studies the following conditions: Interstitial Cystitis, Bladder Pain Syndrome, Chronic Interstitial Cystitis.
What interventions are being tested in trial NCT04734106?
The interventions under investigation include: Desert Harvest Aloe Vera Capsules (DRUG), Placebo Capsules (OTHER).
Who is sponsoring clinical trial NCT04734106?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04734106 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Cystitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04734106's enrollment target sits among peer trials
30 20th of 26 higher than 7 of 26 other Interstitial Cystitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Interstitial Cystitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome
ACTIVE NOT RECRUITING · Early Phase 1
-
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
RECRUITING · NA
-
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
RECRUITING · Phase 1
-
Motor Cortical Neuromodulation in Women With Interstitial Cystitis/Bladder Pain Syndrome
RECRUITING · NA
-
Identifying Genetic Causes of IC/BPS
RECRUITING
-
EPPIC: Easing Pelvic Pain Interventions Clinical Research Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI